Top ▲

H1 receptor

Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Target id: 262

Nomenclature: H1 receptor

Family: Histamine receptors

Contents:

Gene and Protein Information Click here for help
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 487 3p25.3 HRH1 histamine receptor H1 18-19,27,50,70
Mouse 7 488 6 53.05 cM Hrh1 histamine receptor H1 39
Rat 7 486 4q42 Hrh1 histamine receptor H 1 25
Previous and Unofficial Names Click here for help
H1R | HH1R | Hisr
Database Links Click here for help
Specialist databases
GPCRdb hrh1_human (Hs), hrh1_mouse (Mm), hrh1_rat (Rn)
Other databases
Alphafold P35367 (Hs), P70174 (Mm), P31390 (Rn)
ChEMBL Target CHEMBL231 (Hs), CHEMBL4322 (Mm), CHEMBL4701 (Rn)
DrugBank Target P35367 (Hs)
Ensembl Gene ENSG00000196639 (Hs), ENSMUSG00000053004 (Mm), ENSRNOG00000007420 (Rn)
Entrez Gene 3269 (Hs), 15465 (Mm), 24448 (Rn)
Human Protein Atlas ENSG00000196639 (Hs)
KEGG Gene hsa:3269 (Hs), mmu:15465 (Mm), rno:24448 (Rn)
OMIM 600167 (Hs)
Pharos P35367 (Hs)
RefSeq Nucleotide NM_000861 (Hs), NM_008285 (Mm), NM_017018 (Rn)
RefSeq Protein NP_000852 (Hs), NP_032311 (Mm), NP_058714 (Rn)
SynPHARM 2980 (in complex with doxepin)
9220 (in complex with [11C]doxepin)
UniProtKB P35367 (Hs), P70174 (Mm), P31390 (Rn)
Wikipedia HRH1 (Hs)
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  Histamine H1 receptor in complex with antagonist
PDB Id:  3RZE
Ligand:  doxepin
Resolution:  3.1Å
Species:  Human
References:  85
Natural/Endogenous Ligands Click here for help
histamine

Download all structure-activity data for this target as a CSV file go icon to follow link

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
dimethylhistaprodifen Small molecule or natural product Hs Full agonist 6.4 pKi 84
⤷ pKi 6.4 [84]
methylhistaprodifen Small molecule or natural product Hs Full agonist 6.4 pKi 84
⤷ pKi 6.4 (Ki 3.98x10-7 M) [84]
ST-1006 Small molecule or natural product Click here for species-specific activity table Hs Agonist <6.0 pKi 77
⤷ pKi <6.0 (Ki >1x10-6 M) [77]
2-(3-iodophenyl)histamine Small molecule or natural product Hs Full agonist 5.8 pKi 84
⤷ pKi 5.8 [84]
2-(3-bromophenyl)histamine Small molecule or natural product Click here for species-specific activity table Hs Full agonist 5.7 pKi 84
⤷ pKi 5.7 [84]
2-(3-chlorophenyl)histamine Small molecule or natural product Hs Full agonist 5.7 pKi 84
⤷ pKi 5.7 [84]
histaprodifen Small molecule or natural product Hs Full agonist 5.7 pKi 53
⤷ pKi 5.7 [53]
2-(2-thiazolyl)ethanamine Small molecule or natural product Hs Partial agonist 5.3 pKi 84
⤷ pKi 5.3 [84]
histamine Small molecule or natural product Click here for species-specific activity table Ligand is endogenous in the given species Ligand has a PDB structure Immunopharmacology Ligand Hs Full agonist 4.7 – 5.9 pKi 8,70,80,84,94
⤷ pKi 4.7 – 5.9 [8,70,80,84,94]
UR-PG55B Small molecule or natural product Hs Full agonist 5.2 pKi 94
⤷ pKi 5.2 [94]
UR-PG131A Small molecule or natural product Hs Full agonist 4.7 pKi 94
⤷ pKi 4.7 [94]
UR-PG153 Small molecule or natural product Hs Full agonist 4.7 pKi 94
⤷ pKi 4.7 [94]
oxo-arpromidine Small molecule or natural product Click here for species-specific activity table Hs Full agonist 4.5 pKi 94
⤷ pKi 4.5 [94]
UR-PG146 Small molecule or natural product Click here for species-specific activity table Hs Full agonist 4.4 pKi 94
⤷ pKi 4.4 [94]
2-pyridylethylamine Small molecule or natural product Immunopharmacology Ligand Hs Full agonist 3.7 pKi 80
⤷ pKi 3.7 [80]
vilazodone Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Agonist 6.5 pIC50 35
⤷ pIC50 6.5 (IC50 3.17x10-7 M) [35]
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
[11C]doxepin Small molecule or natural product Ligand is labelled Ligand is radioactive Ligand has a PDB structure Hs Antagonist 9.0 pKd 41
⤷ pKd 9.0 (Kd 1x10-9 M) [41]
[3H]pyrilamine Small molecule or natural product Click here for species-specific activity table Ligand is labelled Ligand is radioactive Hs Inverse agonist 8.4 – 9.1 pKd 19,70,83-84
⤷ pKd 8.4 – 9.1 (Kd 4x10-9 – 7.9x10-10 M) [19,70,83-84]
tripelennamine Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Antagonist 8.0 pKd 34
⤷ pKd 8.0 (Kd 1x10-8 M) [34]
clemastine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Antagonist 10.3 pKi 3
⤷ pKi 10.3 (Ki 4.9x10-11 M) [3]
cyproheptadine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 10.2 pKi 70
⤷ pKi 10.2 [70]
asenapine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 9.8 pKi 83
⤷ pKi 9.8 [83]
doxepin Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 9.5 – 10.0 pKi 8
⤷ pKi 9.5 – 10.0 [8]
promethazine Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 9.6 pKi 29
⤷ pKi 9.6 (Ki 2.4x10-10 M) [29]
amitriptyline Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 9.3 pKi 29
⤷ pKi 9.3 (Ki 5x10-10 M) [29]
Description: Antagonism of [3H]mepyramine binding
clozapine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 8.8 – 9.6 pKi 8,47,83
⤷ pKi 8.8 – 9.6 [8,47,83]
zotepine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 9.2 pKi 83
⤷ pKi 9.2 [83]
alimemazine Small molecule or natural product Approved drug Immunopharmacology Ligand Bt Antagonist 9.1 pKi 48
⤷ pKi 9.1 (Ki 7.2x10-10 M) [48]
Description: Inhibition of [3H]mepyramine binding to bovine brain membrane preparations in vitro.
desloratadine Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Immunopharmacology Ligand Hs Antagonist 9.0 pKi 51
⤷ pKi 9.0 (Ki 9.7x10-10 M) [51]
olanzapine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 8.7 – 9.2 pKi 47,83
⤷ pKi 8.7 – 9.2 [47,83]
azelastine Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 8.9 pKi 79
⤷ pKi 8.9 (Ki 1.26x10-9 M) [79]
mepyramine Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Immunopharmacology Ligand Hs Inverse agonist 8.7 – 9.0 pKi 8,80
⤷ pKi 8.7 – 9.0 [8,80]
triprolidine Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 8.5 – 9.0 pKi 8,70
⤷ pKi 8.5 – 9.0 (Ki 3.16x10-9 – 1x10-9 M) [8,70]
(-)-trans-H2-PAT Small molecule or natural product Hs Antagonist 8.6 – 8.8 pKi 8
⤷ pKi 8.6 – 8.8 [8]
hydroxyzine Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Antagonist 8.7 pKi 31
⤷ pKi 8.7 (Ki 1.99x10-9 M) [31]
ketotifen Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 8.6 pKi 49
⤷ pKi 8.6 (Ki 2.5x10-9 M) [49]
mizolastine Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Antagonist 8.6 pKi 13
⤷ pKi 8.6 (Ki 2.7x10-9 M) [13]
Description: Radioligand displacement membrane binding assay using CHO cells expressing the human H1 receptor and [3H]pyrilamine as tracer.
astemizole Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 8.5 pKi 78
⤷ pKi 8.5 (Ki 3x10-9 M) [78]
(±)-trans-H2-PAT Small molecule or natural product Hs Antagonist 8.4 – 8.6 pKi 8
⤷ pKi 8.4 – 8.6 [8]
(R)-cetirizine Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Hs Inverse agonist 8.5 pKi 80
⤷ pKi 8.5 [80]
(+)-chlorpheniramine Small molecule or natural product Hs Antagonist 8.3 – 8.6 pKi 8,70
⤷ pKi 8.3 – 8.6 [8,70]
chlorprothixene Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 8.4 pKi 91
⤷ pKi 8.4 (Ki 3.75x10-9 M) [91]
thiothixene Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 8.4 pKi 47
⤷ pKi 8.4 [47]
dosulepin Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 8.4 pKi 87
⤷ pKi 8.4 (Ki 4x10-9 M) [87]
quetiapine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 8.0 – 8.7 pKi 47,83
⤷ pKi 8.0 – 8.7 [47,83]
cyclizine Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 8.4 pKi 3
⤷ pKi 8.4 (Ki 4.44x10-9 M) [3]
chlorpromazine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 8.2 pKi 47
⤷ pKi 8.2 [47]
loxapine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 8.2 pKi 47
⤷ pKi 8.2 [47]
cetirizine Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Inverse agonist 8.2 pKi 70
⤷ pKi 8.2 [70]
chlorpheniramine Small molecule or natural product Approved drug Primary target of this compound Hs Antagonist 8.1 pKi 79
⤷ pKi 8.1 (Ki 7x10-9 M) [79]
perphenazine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 8.1 pKi 47
⤷ pKi 8.1 [47]
(±)-cis-H2-PAT Small molecule or natural product Hs Antagonist 7.8 – 8.2 pKi 8
⤷ pKi 8.1 – 8.2 [8]
pKi 7.8 – 7.9 [8]
fluspirilene Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 7.9 pKi 83
⤷ pKi 7.9 [83]
diphenhydramine Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Hs Antagonist 7.9 pKi 8
⤷ pKi 7.9 [8]
risperidone Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 7.6 – 7.8 pKi 47,83
⤷ pKi 7.6 – 7.8 [47,83]
thioridazine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 7.7 pKi 47
⤷ pKi 7.7 [47]
fluphenazine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 7.7 pKi 47
⤷ pKi 7.7 [47]
ziprasidone Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 7.4 – 7.8 pKi 47,83
⤷ pKi 7.4 – 7.8 [47,83]
fexofenadine Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Antagonist 7.6 pKi 2
⤷ pKi 7.6 (Ki 2.7x10-8 M) [2]
aripiprazole Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 7.5 pKi 47
⤷ pKi 7.5 [47]
9-OH-risperidone Small molecule or natural product Click here for species-specific activity table Hs Antagonist 7.5 pKi 83
⤷ pKi 7.5 [83]
AZD3778 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 7.5 pKi 5
⤷ pKi 7.5 (Ki 3.16x10-8 M) [5]
Description: Assayed using the sodium salt of the compound
(+)-trans-H2-PAT Small molecule or natural product Hs Antagonist 7.4 – 7.5 pKi 8
⤷ pKi 7.4 – 7.5 [8]
loratadine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Antagonist 7.4 pKi 44
⤷ pKi 7.4 (Ki 3.7x10-8 M) [44]
terfenadine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Antagonist 7.4 pKi 2
⤷ pKi 7.4 (Ki 4x10-8 M) [2]
trifluoperazine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 7.2 pKi 47
⤷ pKi 7.2 [47]
bilastine Small molecule or natural product Approved drug Hs Antagonist 7.2 pKi 14
⤷ pKi 7.2 (Ki 6.4x10-8 M) [14]
Description: Binding to human recombinant histamine H1 receptors
(S)-dimetindene Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Antagonist 7.2 pKi 11
⤷ pKi 7.2 (Ki 6.9x10-8 M) [11]
rupatadine Small molecule or natural product Approved drug Immunopharmacology Ligand Cp Antagonist 7.0 pKi 64
⤷ pKi 7.0 (Ki 1x10-7 M) [64]
Description: [3H]-pyrilamine binding to guinea pig cerebellum membranes.
sertindole Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 6.9 pKi 47,83
⤷ pKi 6.9 [47,83]
(+)-cis-H2-PAT Small molecule or natural product Hs Antagonist 6.9 pKi 8
⤷ pKi 6.9 [8]
(S)-cetirizine Small molecule or natural product Ligand has a PDB structure Hs Inverse agonist 6.7 pKi 80
⤷ pKi 6.7 [80]
BU-E 47 Small molecule or natural product Hs Antagonist 6.6 pKi 84
⤷ pKi 6.6 [84]
(-)-chlorpheniramine Small molecule or natural product Hs Antagonist 6.4 – 6.7 pKi 8
⤷ pKi 6.4 – 6.7 [8]
arpromidine Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Antagonist 6.5 pKi 84,94
⤷ pKi 6.5 [84,94]
pimozide Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 6.2 pKi 47
⤷ pKi 6.2 [47]
JNJ-39758979 Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Antagonist <6.0 pKi 77
⤷ pKi <6.0 (Ki >1x10-6 M) [77]
haloperidol Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Antagonist 5.7 – 6.1 pKi 47,83
⤷ pKi 5.7 – 6.1 [47,83]
ABT-239 Small molecule or natural product Click here for species-specific activity table Hs Inverse agonist 5.8 pKi 23
⤷ pKi 5.8 [23]
pitolisant Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 5.8 pKi 77
⤷ pKi 5.8 [77]
molindone Small molecule or natural product Approved drug Click here for species-specific activity table Hs Antagonist 5.7 pKi 47
⤷ pKi 5.7 [47]
pipamperone Small molecule or natural product Click here for species-specific activity table Hs Antagonist 5.6 pKi 83
⤷ pKi 5.6 [83]
A-349821 Small molecule or natural product Click here for species-specific activity table Hs Inverse agonist 5.6 pKi 22
⤷ pKi 5.6 [22]
clobenpropit Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Antagonist 5.6 pKi 24
⤷ pKi 5.6 [24]
A-317920 Small molecule or natural product Click here for species-specific activity table Hs Antagonist 5.4 pKi 22,24
⤷ pKi 5.4 [22,24]
impromidine Small molecule or natural product Click here for species-specific activity table Immunopharmacology Ligand Hs Antagonist 5.2 pKi 94
⤷ pKi 5.2 [94]
ciproxifan Small molecule or natural product Click here for species-specific activity table Hs Antagonist <5.0 pKi 77
⤷ pKi <5.0 (Ki >1x10-5 M) [77]
MK-0249 Small molecule or natural product Click here for species-specific activity table Hs Antagonist <5.0 pKi 77
⤷ pKi <5.0 (Ki >1x10-5 M) [77]
conessine Small molecule or natural product Click here for species-specific activity table Hs Antagonist <5.0 pKi 77
⤷ pKi <5.0 (Ki >1x10-5 M) [77]
INCB-38579 Small molecule or natural product Click here for species-specific activity table Hs Antagonist <5.0 pKi 77
⤷ pKi <5.0 (Ki >1x10-5 M) [77]
rupatadine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Immunopharmacology Ligand Hs Antagonist 8.4 pIC50 73
⤷ pIC50 8.4 (IC50 3.9x10-9 M) [73]
epinastine Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Antagonist 7.6 pIC50 37
⤷ pIC50 7.6 (IC50 2.5x10-8 M) [37]
Description: Antagonism of 5 nM [3H]mepyramine binding in an intact cell assay using U373 MG astrocytoma cells.
tripelennamine Small molecule or natural product Approved drug Primary target of this compound Immunopharmacology Ligand Hs Antagonist 7.4 pIC50 34
⤷ pIC50 7.4 (IC50 3.98x10-8 M) [34]
mizolastine Small molecule or natural product Approved drug Immunopharmacology Ligand Cp Antagonist 7.3 pIC50 6
⤷ pIC50 7.3 (IC50 4.7x10-8 M) [6]
Description: Inhibition of [3H]pyrilamine binding to histamine H1 receptors in guinea pig cerebellar membranes and sections.
[11C]pyrilamine Small molecule or natural product Ligand is labelled Ligand is radioactive Ligand has a PDB structure Hs Inverse agonist - -
⤷
View species-specific antagonist tables
Antagonist Comments
Astemizole is highly selective for the histamine H1 receptor over the H2 receptor.
Immunopharmacology Comments
The H1 receptor was the first of the family to be targeted for clinical use, with antagonists (anti-histamines) developed that are still used widely to treat allergic inflammation such as rhinitis, allergic conjunctivitis, urticaria and even anaphylaxis.
Cell Type Associations
Immuno Cell Type:  Granulocytes
Cell Ontology Term:   eosinophil (CL:0000771)
Comment:  Eosinophils express all four histamine receptor subtypes.
References:  30,65
Immuno Cell Type:  Mast cells
Cell Ontology Term:   mast cell (CL:0000097)
Comment:  In humans, mast cells express H1R, H2R and H4R.
References:  28
Immuno Process Associations
Immuno Process:  Inflammation
Immuno Process:  Chemotaxis & migration
Primary Transduction Mechanisms Click here for help
Transducer Effector/Response
Gq/G11 family Adenylyl cyclase stimulation
Comments:  Stimulation of cAMP accumulation is via Gβγ subunits of Gq [59].
References:  59
Secondary Transduction Mechanisms Click here for help
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
References:  52
Tissue Distribution Click here for help
Brain: cerebrum.
Heart: myocardium (ventricle > atrium).
Species:  Human
Technique:  Northern and Western blotting.
References:  63
Brain.
Species:  Human
Technique:  Positron emission tomography (PET).
References:  69
Cranial arteries.
Species:  Human
Technique:  RT-PCR.
References:  43
Myometrium.
Species:  Human
Technique:  Radioligand binding.
References:  32
Gastrointestinal tract.
Species:  Human
Technique:  qRT-PCR and immunohistochemistry.
References:  81
Uterine horns.
Species:  Mouse
Technique:  Radioligand binding.
References:  33
Mast cells.
Species:  Mouse
Technique:  RT-PCR.
References:  38
Sympathetic preganglionic neurons in the spinal cord.
Species:  Rat
Technique:  RT-PCR.
References:  92
Embryonic brain and spinal cord.
Species:  Rat
Technique:  in situ hybridization, RT-PCR and Northern blotting.
References:  46
Brain: cerebrum.
Heart: myocardium (atrium and ventricle).
Species:  Rat
Technique:  Northern and Western blotting.
References:  63
Cochlea.
Species:  Rat
Technique:  RT-PCR.
References:  4
Expression Datasets Click here for help

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays Click here for help
Measurement of IP levels in COS-7 cells transfected with the human H1 receptor.
Species:  Human
Tissue:  COS-7 cells.
Response measured:  Stimulation of IP formation.
References:  18
Measurement of IP levels in CHO cells transfected with the human H1 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of IP formation.
References:  8
Measurement of AC activity in baculovirus-infected Sf9 insect cells expressing the human H1 receptor.
Species:  Human
Tissue:  Sf9 cells.
Response measured:  Stimulation of AC activity.
References:  94
Measurement of cAMP levels in CHO cells transfected with the human H1 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of cAMP accumulation.
References:  59
Measurement of PLC activity and Ca2+ mobilisation in cultured ciliary muscle cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Cultured ciliary muscle cells.
Response measured:  Activation of PLC and mobilisation of both intracellular and extracellular Ca2+.
References:  57
Measurement of IP levels in cultured human endothelial cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Cultured umbilical vein endothelial cells.
Response measured:  Stimulation of IP formation.
References:  54
Measurement of mitogenesis in human astrocytoma U373 MG cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Astrocytoma U373 MG cells.
Response measured:  Cell proliferation via PKC and MAPK.
References:  36
Measurement of Ca2+ levels as well as ERK1/2 and PKC activity in human primary epithelial cells and the NCI-H292 cell line, both endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Primary epithelial cells and the NCI-H292 cell line.
Response measured:  Elevation of Ca2+ levels and activation of PKC and ERK1/2.
References:  62
Measurement of IP, DAG and Ca2+ levels in human HeLa carcinoma cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  HeLa carcinoma cells.
Response measured:  Formation of IP and DAG and a rise in Ca2+ levels.
References:  89
Physiological Functions Click here for help
Bronchoconstriction.
Species:  Human
Tissue:  In vivo.
References:  12,15,20,55,74,88
Relaxation of smooth muscle (via an endothelial H1 receptor).
Species:  Human
Tissue:  Cranial arteries.
References:  43
Contraction of smooth muscle.
Species:  Human
Tissue:  Arterial rings.
References:  17
Modulation of adrenergic neurotransmission.
Species:  Rat
Tissue:  Vas deferens.
References:  90
Inhibition of locomotor behaviour.
Species:  Rat
Tissue:  In vivo.
References:  1
Modulation of feeding behaviour.
Species:  Rat
Tissue:  In vivo.
References:  26
Modulation of feeding behaviour.
Species:  Mouse
Tissue:  In vivo.
References:  60-61,71-72
Hypernociception.
Species:  Rat
Tissue:  In vivo.
References:  56
Endothelium-dependent vasodilation.
Species:  Rat
Tissue:  Mesenteric vascular beds.
References:  45
Role in the stimulation of skin blood flow during whole body heating.
Species:  Human
Tissue:  In vivo.
References:  93
Stimulation of the nitric oxide signalling system.
Species:  Rat
Tissue:  Submandibular gland.
References:  9
Increased vascular permeability.
Species:  Mouse
Tissue:  In vivo.
References:  7,75
Modulation of neuronal firing.
Species:  Rat
Tissue:  Dorsal raphe nucleus.
References:  10
Contraction of smooth muscle.
Species:  Human
Tissue:  Isolated uterine strips.
References:  58
Contraction of smooth muscle.
Species:  Rat
Tissue:  Isolated stomach fundus.
References:  21
Increase in substantia nigra pars reticulata (SNr) inhibitory projection neuron firing frequency (via cell depolarisation).
The balance between the effect of H1 and H2 receptors and the opposing effect of H3 receptors may contribute to movement control.
Species:  Mouse
Tissue:  Coronal midbrain slices.
References:  97
Depolarisation.
Species:  Rat
Tissue:  Sympathetic preganglionic neurons.
References:  92
Regulation of cytokine production.
Species:  Mouse
Tissue:  CD4+ and CD8+ T cells.
References:  86
Prostacyclin formation.
Species:  Human
Tissue:  Pulmonary artery.
References:  82
Physiological Consequences of Altering Gene Expression Click here for help
H1 receptor knockout mice develop normally, but exhibit impaired locomotor activity and exploratory behavior.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  40,96
H1 receptor knockout mice subjected to social isolation after weaning exhibit similar levels of locomotor activity to socially reared H1 receptor knockout mice. This is in contrast to wild-type mice, where there is a significant decrease in locomotor activity in socially isolated WT mice compared with socially reared WT mice. It is suggested that blockade of H1 receptors by atypical antipsychotics attenuates social isolation-induced behavioral changes.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  16
H1 receptor knockout mice exhibit decreased exploratory activity, reduced levels of anxiety and aggression, a decrease in nociceptive response and an increased 5-HT turnover rate in the cerebral cortex and hippocampus.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  95
H1 receptor knockout mice exhibit a significant decrease in nociception compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  67
H1 knockout mice exhibit enhancement of morphine-induced antinociception.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  66
H1 receptor knockout mice do not exhibit an increase in respiratory frequency upon elevation of body temperature, as observed in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  42
H1 receptor knockout mice exhibit a reduction in the effect of neurotensin on the supression of food intake.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  76
H1 receptor knockout mice do not exhibit an increase in vascular permeability of the conjunctiva, as observed in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  75
CD4+ T cells from H1 receptor knockout mice exhibit a decrease in the release of Il-2 and Il-10, and an increase in the release of IL-4. CD8+ T cells from H1 receptor knockout mice also exhibit a decrease in the release of Il-2 and Il-10, as well as an increase in the release of IFN-γ.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  86
H1 receptor knockout mice exhibit enhanced antinociception by administration of orexin-A, compared to wild-type mice following administration of orexin-A.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  68
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6		 MGI:107619  MP:0004924 abnormal behavior PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6		 MGI:107619  MP:0001502 abnormal circadian rhythm PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6		 MGI:107619  MP:0005093 decreased B cell proliferation PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0001262 decreased body weight PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0002727 decreased circulating insulin level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0003910 decreased eating behavior PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6		 MGI:107619  MP:0001417 decreased exploration in new environment PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6		 MGI:107619  MP:0008498 decreased IgG3 level PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6		 MGI:107619  MP:0001806 decreased IgM level PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0001876 decreased inflammatory response PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6		 MGI:107619  MP:0008567 decreased interferon-gamma secretion PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0008567 decreased interferon-gamma secretion PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0008673 decreased interleukin-13 secretion PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6		 MGI:107619  MP:0008688 decreased interleukin-2 secretion PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0008703 decreased interleukin-5 secretion PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6		 MGI:107619  MP:0005018 decreased T cell number PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6		 MGI:107619  MP:0005095 decreased T cell proliferation PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0010025 decreased total body fat amount PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6		 MGI:107619  MP:0002757 decreased vertical activity PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0001260 increased body weight PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0000005 increased brown adipose tissue amount PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0001554 increased circulating free fatty acid level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0005669 increased circulating leptin level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0003909 increased eating behavior PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0006094 increased fat cell size PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0002493 increased IgG level PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0002494 increased IgM level PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6		 MGI:107619  MP:0008699 increased interleukin-4 secretion PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0009355 increased liver triglyceride level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0005317 increased triglyceride level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1		 MGI:107619  MP:0000008 increased white adipose tissue amount PMID: 15331534 

References

Show »

1. Alvarez EO, Banzán AM. (1986) Histamine in dorsal and ventral hippocampus. II. Effects of H1 and H2 histamine antagonists on exploratory behavior in male rats. Physiol Behav, 37: 39-45. [PMID:3016772]

2. Aslanian R, Piwinski JJ, Zhu X, Priestley T, Sorota S, Du XY, Zhang XS, McLeod RL, West RE, Williams SM et al.. (2009) Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg Med Chem Lett, 19 (17): 5043-7. [PMID:19660947]

3. Auerbach SS, DrugMatrix® and ToxFX® Coordinator National Toxicology Program. National Toxicology Program: Dept of Health and Human Services. Accessed on 02/05/2014. Modified on 02/05/2014. DrugMatrix, https://ntp.niehs.nih.gov/drugmatrix/index.html

4. Azuma H, Sawada S, Takeuchi S, Higashiyama K, Kakigi A, Takeda T. (2003) Expression of mRNA encoding the H1, H2, and H3 histamine receptors in the rat cochlea. Neuroreport, 14 (3): 423-5. [PMID:12634496]

5. Bahl A, Barton P, Bowers K, Brough S, Evans R, Luckhurst CA, Mochel T, Perry MW, Rigby A, Riley RJ et al.. (2012) The discovery of CCR3/H1 dual antagonists with reduced hERG risk. Bioorg Med Chem Lett, 22 (21): 6688-93. [PMID:23031591]

6. Benavides J, Schoemaker H, Dana C, Claustre Y, Delahaye M, Prouteau M, Manoury P, Allen J, Scatton B, Langer SZ et al.. (1995) In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent. Arzneimittelforschung, 45 (5): 551-8. [PMID:7612054]

7. Bhargava KP, Nath R, Palit G. (1977) Nature of histamine receptors concerned in capillary permeability. Br J Pharmacol, 59: 349-351. [PMID:837022]

8. Booth RG, Moniri NH, Bakker RA, Choksi NY, Nix WB, Timmerman H, Leurs R. (2002) A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. J Pharmacol Exp Ther, 302 (1): 328-36. [PMID:12065734]

9. Borda E, Stranieri G, Sterin-Borda L. (2002) H(1)-Receptor activation triggers the endogenous nitric oxide signalling system in the rat submandibular gland. Mediators Inflamm, 11: 337-343. [PMID:12581497]

10. Bárbara A, Aceves J, Arias-Montaño JA. (2002) Histamine H1 receptors in rat dorsal raphe nucleus: pharmacological characterisation and linking to increased neuronal activity. Brain Res, 954 (2): 247-55. [PMID:12414108]

11. Böhme TM, Keim C, Kreutzmann K, Linder M, Dingermann T, Dannhardt G, Mutschler E, Lambrecht G. (2003) Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists. J Med Chem, 46 (5): 856-67. [PMID:12593665]

12. Casterline CL, Evans R. (1977) Further studies on the mechanism of human histamine-induced asthma: the effect of an aerosolized H1 receptor antagonist (diphenhydramine). J Allergy Clin Immunol, 59 (6): 420-4. [PMID:16944]

13. Coon T, Moree WJ, Li B, Yu J, Zamani-Kord S, Malany S, Santos MA, Hernandez LM, Petroski RE, Sun A et al.. (2009) Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia. Bioorg Med Chem Lett, 19 (15): 4380-4. [PMID:19553115]

14. Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. (2005) Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D, 6 (6): 371-84. [PMID:16274260]

15. Crimi N, Polosa R, Magrì S, Prosperini G, Paolino G, Mastruzzo C, Mistretta A. (1996) Inhaled lysine acetylsalicylate (L-ASA) attenuates histamine-induced bronchoconstriction in asthma. Allergy, 51 (3): 157-63. [PMID:8781669]

16. Dai H, Okuda T, Sakurai E, Kuramasu A, Kato M, Jia F, Xu AJ, Iinuma K, Sato I, Yanai K. (2005) Blockage of histamine H1 receptor attenuates social isolation-induced disruption of prepulse inhibition: a study in H1 receptor gene knockout mice. Psychopharmacology (Berl.), 183 (3): 285-93. [PMID:16237577]

17. Daneshmand MA, Keller RS, Canver MC, Canver AC, Canver CC. (2004) Histamine H1 and H2 receptor-mediated vasoreactivity of human internal thoracic and radial arteries. Surgery, 136 (2): 458-63. [PMID:15300215]

18. De Backer MD, Gommeren W, Moereels H, Nobels G, Van Gompel P, Leysen JE, Luyten WH. (1993) Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor. Biochem Biophys Res Commun, 197 (3): 1601-8. [PMID:8280179]

19. De Backer MD, Loonen I, Verhasselt P, Neefs JM, Luyten WH. (1998) Structure of the human histamine H1 receptor gene. Biochem J, 335 ( Pt 3): 663-70. [PMID:9794809]

20. Eiser NM, Mills J, Snashall PD, Guz A. (1981) The role of histamine receptors in asthma. Clin Sci (Lond.), 60: 363-370. [PMID:7249528]

21. Ercan ZS, Türker RK. (1977) Histamine receptors in the isolated rat stomach fundus and rabbit aortic strips. Pharmacology, 15 (2): 118-26. [PMID:847009]

22. Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB et al.. (2004) Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem Pharmacol, 68 (5): 933-45. [PMID:15294456]

23. Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J et al.. (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J Pharmacol Exp Ther, 313 (1): 165-75. [PMID:15608078]

24. Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL et al.. (2003) Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J Pharmacol Exp Ther, 305 (3): 887-96. [PMID:12606603]

25. Fujimoto K, Horio Y, Sugama K, Ito S, Liu YQ, Fukui H. (1993) Genomic cloning of the rat histamine H1 receptor. Biochem Biophys Res Commun, 190 (1): 294-301. [PMID:7678492]

26. Fukagawa K, Sakata T, Shiraishi T, Yoshimatsu H, Fujimoto K, Ookuma K, Wada H. (1989) Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. Am J Physiol, 256: R605-R611. [PMID:2564258]

27. Fukui H, Fujimoto K, Mizuguchi H, Sakamoto K, Horio Y, Takai S, Yamada K, Ito S. (1994) Molecular cloning of the human histamine H1 receptor gene. Biochem Biophys Res Commun, 201 (2): 894-901. [PMID:8003029]

28. Gangwar RS, Landolina N, Arpinati L, Levi-Schaffer F. (2017) Mast cell and eosinophil surface receptors as targets for anti-allergic therapy. Pharmacol Ther, 170: 37-63. [PMID:27773785]

29. Ghoneim OM, Legere JA, Golbraikh A, Tropsha A, Booth RG. (2006) Novel ligands for the human histamine H1 receptor: synthesis, pharmacology, and comparative molecular field analysis studies of 2-dimethylamino-5-(6)-phenyl-1,2,3,4-tetrahydronaphthalenes. Bioorg Med Chem, 14 (19): 6640-58. [PMID:16782354]

30. Gibbs BF, Levi-Schaffer F. (2012) H₄ receptors in mast cells and basophils: a new therapeutic target for allergy?. Front Biosci (Landmark Ed), 17: 430-7. [PMID:22201753]

31. Gillard M, Van Der Perren C, Moguilevsky N, Massingham R, Chatelain P. (2002) Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol Pharmacol, 61 (2): 391-9. [PMID:11809864]

32. Gonzalez R, Echeverria E, Reinicke K, Rudolph MI. (1994) Increased affinity of histamine H1 binding to membranes of human myometrium at the end of pregnancy. Gen Pharmacol, 25 (8): 1607-10. [PMID:7721035]

33. Gonzalez R, Reinicke K, Rudolph GM. (1993) Histamine H1 receptor binding sites in mouse uterine horns. Gen Pharmacol, 24 (1): 29-33. [PMID:8482504]

34. Govoni M, Bakker RA, van de Wetering I, Smit MJ, Menge WM, Timmerman H, Elz S, Schunack W, Leurs R. (2003) Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists. J Med Chem, 46 (26): 5812-24. [PMID:14667234]

35. Heinrich T, Böttcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, Van Amsterdam C. (2004) Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J Med Chem, 47 (19): 4684-92. [PMID:15341484]

36. Hernández-Angeles A, Soria-Jasso LE, Ortega A, Arias-Montaño JA. (2001) Histamine H1 receptor activation stimulates mitogenesis in human astrocytoma U373 MG cells. J Neurooncol, 55 (2): 81-9. [PMID:11817705]

37. Hishinuma S, Sato Y, Kobayashi Y, Komazaki H, Saito M. (2008) Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci, 107 (1): 66-79. [PMID:18446005]

38. Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP. (2003) Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther, 305 (3): 1212-21. [PMID:12626656]

39. Inoue I, Taniuchi I, Kitamura D, Jenkins NA, Gilbert DJ, Copeland NG, Watanabe T. (1996) Characteristics of the mouse genomic histamine H1 receptor gene. Genomics, 36 (1): 178-81. [PMID:8812432]

40. Inoue I, Yanai K, Kitamura D, Taniuchi I, Kobayashi T, Niimura K, Watanabe T, Watanabe T. (1996) Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci USA, 93 (23): 13316-20. [PMID:8917588]

41. Ishiwata K, Kawamura K, Wang WF, Tsukada H, Harada N, Mochizuki H, Kimura Y, Ishii K, Iwata R, Yanai K. (2004) Evaluation of in vivo selective binding of [11C]doxepin to histamine H1 receptors in five animal species. Nucl Med Biol, 31 (4): 493-502. [PMID:15093820]

42. Izumizaki M, Iwase M, Kimura H, Yanai K, Watanabe T, Homma I. (2000) Lack of temperature-induced polypnea in histamine H1 receptor-deficient mice. Neurosci Lett, 284 (3): 139-42. [PMID:10773418]

43. Jansen-Olesen I, Ottosson A, Cantera L, Strunk S, Lassen LH, Olesen J, Mortensen A, Engel U, Edvinsson L. (1997) Role of endothelium and nitric oxide in histamine-induced responses in human cranial arteries and detection of mRNA encoding H1- and H2-receptors by RT-PCR. Br J Pharmacol, 121: 41-48. [PMID:9146885]

44. Janssens F, Leenaerts J, Diels G, De Boeck B, Megens A, Langlois X, van Rossem K, Beetens J, Borgers M. (2005) Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines. J Med Chem, 48 (6): 2154-66. [PMID:15771458]

45. Jin H, Koyama T, Hatanaka Y, Akiyama S, Takayama F, Kawasaki H. (2006) Histamine-induced vasodilation and vasoconstriction in the mesenteric resistance artery of the rat. Eur J Pharmacol, 529 (1-3): 136-44. [PMID:16337938]

46. Kinnunen A, Lintunen M, Karlstedt K, Fukui H, Panula P. (1998) In situ detection of H1-receptor mRNA and absence of apoptosis in the transient histamine system of the embryonic rat brain. J Comp Neurol, 394 (1): 127-37. [PMID:9550146]

47. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology, 28 (3): 519-26. [PMID:12629531]

48. Kubo N, Shirakawa O, Kuno T, Tanaka C. (1987) Antimuscarinic effects of antihistamines: quantitative evaluation by receptor-binding assay. Jpn J Pharmacol, 43 (3): 277-82. [PMID:2884340]

49. Kubota K, Kurebayashi H, Miyachi H, Tobe M, Onishi M, Isobe Y. (2011) Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines. Bioorg Med Chem, 19 (9): 3005-21. [PMID:21470866]

50. Le Coniat M, Traiffort E, Ruat M, Arrang JM, Berger R. (1994) Chromosomal localization of the human histamine H1-receptor gene. Hum Genet, 94 (2): 186-8. [PMID:8045566]

51. Lewis TA, Young MA, Arrington MP, Bayless L, Cai X, Collart P, Eckman JB, Ellis JL, Ene DG, Libertine L et al.. (2004) Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett, 14 (22): 5591-4. [PMID:15482930]

52. Li H, Choe NH, Wright DT, Adler KB. (1995) Histamine provokes turnover of inositol phospholipids in guinea pig and human airway epithelial cells via an H1-receptor/G protein-dependent mechanism. Am J Respir Cell Mol Biol, 12 (4): 416-24. [PMID:7695921]

53. Lim HD, van Rijn RM, Ling P, Bakker RA, Thurmond RL, Leurs R. (2005) Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist. J Pharmacol Exp Ther, 314 (3): 1310-21. [PMID:15947036]

54. Lo WW, Fan TP. (1987) Histamine stimulates inositol phosphate accumulation via the H1-receptor in cultured human endothelial cells. Biochem Biophys Res Commun, 148 (1): 47-53. [PMID:3675593]

55. Maconochie JG, Woodings EP, Richards DA. (1979) Effects of H1- and H2-receptor blocking agents on histamine-induced bronchoconstriction in non-asthmatic subjects. Br J Clin Pharmacol, 7 (3): 231-6. [PMID:34415]

56. Malmberg-Aiello P, Lamberti C, Ipponi A, Bartolini A, Schunack W. (1998) Evidence for hypernociception induction following histamine H1 receptor activation in rodents. Life Sci, 63 (6): 463-76. [PMID:9718070]

57. Markwardt KL, Magnino PE, Pang IH. (1996) Effect of histamine on phosphoinositide turnover and intracellular calcium in human ciliary muscle cells. Exp Eye Res, 62 (5): 511-20. [PMID:8759520]

58. Martínez-Mir MI, Estañ L, Morales-Olivas FJ, Rubio E. (1992) Effect of histamine and histamine analogues on human isolated myometrial strips. Br J Pharmacol, 107 (2): 528-31. [PMID:1358393]

59. Maruko T, Nakahara T, Sakamoto K, Saito M, Sugimoto N, Takuwa Y, Ishii K. (2005) Involvement of the βγ subunits of G proteins in the cAMP response induced by stimulation of the histamine H1 receptor. Naunyn Schmiedebergs Arch Pharmacol, 372 (2): 153-9. [PMID:16189696]

60. Masaki T, Chiba S, Yasuda T, Noguchi H, Kakuma T, Watanabe T, Sakata T, Yoshimatsu H. (2004) Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes, 53 (9): 2250-60. [PMID:15331534]

61. Masaki T, Yoshimatsu H, Chiba S, Watanabe T, Sakata T. (2001) Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice. Diabetes, 50: 385-391. [PMID:11272151]

62. Matsubara M, Ohmori K, Hasegawa K. (2006) Histamine H1 receptor-stimulated interleukin 8 and granulocyte macrophage colony-stimulating factor production by bronchial epithelial cells requires extracellular signal-regulated kinase signaling via protein kinase C. Int Arch Allergy Immunol, 139 (4): 279-93. [PMID:16491014]

63. Matsuda N, Jesmin S, Takahashi Y, Hatta E, Kobayashi M, Matsuyama K, Kawakami N, Sakuma I, Gando S, Fukui H et al.. (2004) Histamine H1 and H2 receptor gene and protein levels are differentially expressed in the hearts of rodents and humans. J Pharmacol Exp Ther, 309 (2): 786-95. [PMID:14752062]

64. Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J. (1997) Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther, 280 (1): 114-21. [PMID:8996188]

65. Migalovich-Sheikhet H, Friedman S, Mankuta D, Levi-Schaffer F. (2012) Novel identified receptors on mast cells. Front Immunol, 3: 238. [PMID:22876248]

66. Mobarakeh JI, Sakurada S, Hayashi T, Orito T, Okuyama K, Sakurada T, Kuramasu A, Watanabe T, Watanabe T, Yanai K. (2002) Enhanced antinociception by intrathecally-administered morphine in histamine H1 receptor gene knockout mice. Neuropharmacology, 42 (8): 1079-88. [PMID:12128009]

67. Mobarakeh JI, Sakurada S, Katsuyama S, Kutsuwa M, Kuramasu A, Lin ZY, Watanabe T, Hashimoto Y, Watanabe T, Yanai K. (2000) Role of histamine H(1) receptor in pain perception: a study of the receptor gene knockout mice. Eur J Pharmacol, 391 (1-2): 81-9. [PMID:10720638]

68. Mobarakeh JI, Takahashi K, Sakurada S, Nishino S, Watanabe H, Kato M, Naghdi N, Yanai K. (2005) Enhanced antinociception by intracerebroventricularly administered orexin A in histamine H1 or H2 receptor gene knockout mice. Pain, 118 (1-2): 254-62. [PMID:16202530]

69. Mochizuki H, Kimura Y, Ishii K, Oda K, Sasaki T, Tashiro M, Yanai K, Ishiwata K. (2004) Quantitative measurement of histamine H(1) receptors in human brains by PET and [11C]doxepin. Nucl Med Biol, 31 (2): 165-71. [PMID:15013481]

70. Moguilevsky N, Varsalona F, Noyer M, Gillard M, Guillaume JP, Garcia L, Szpirer C, Szpirer J, Bollen A. (1994) Stable expression of human H1-histamine-receptor cDNA in Chinese hamster ovary cells. Pharmacological characterisation of the protein, tissue distribution of messenger RNA and chromosomal localisation of the gene. Eur J Biochem, 224 (2): 489-95. [PMID:7925364]

71. Mollet A, Lutz TA, Meier S, Riediger T, Rushing PA, Scharrer E. (2001) Histamine H1 receptors mediate the anorectic action of the pancreatic hormone amylin. Am J Physiol Regul Integr Comp Physiol, 281 (5): R1442-8. [PMID:11641114]

72. Morimoto T, Yamamoto Y, Mobarakeh JI, Yanai K, Watanabe T, Watanabe T, Yamatodani A. (1999) Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol Behav, 67 (5): 679-83. [PMID:10604837]

73. Morphy R, Rankovic Z. (2005) Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem, 48 (21): 6523-43. [PMID:16220969]

74. Myou S, Fujimura M, Nishi K, Ohka T, Matsuda T. (1995) Inhibitory effect of terfenadine, a selective H1 histamine antagonist, on alcoholic beverage-induced bronchoconstriction in asthmatic patients. Eur Respir J, 8 (4): 619-23. [PMID:7545133]

75. Nakahara H, Izushi K, Sugimoto Y, Watanabe T, Kamei C. (2000) Vascular permeability in allergic conjunctivitis in mice lacking histamine H1 receptors. Eur J Pharmacol, 409 (3): 313-7. [PMID:11108826]

76. Ohinata K, Shimano T, Yamauchi R, Sakurada S, Yanai K, Yoshikawa M. (2004) The anorectic effect of neurotensin is mediated via a histamine H1 receptor in mice. Peptides, 25 (12): 2135-8. [PMID:15572202]

77. Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WL, Stark H, Thurmond RL, Haas HL. (2015) International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol Rev, 67 (3): 601-55. [PMID:26084539]

78. Pearlstein R, Vaz R, Rampe D. (2003) Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior. J Med Chem, 46 (11): 2017-22. [PMID:12747773]

79. Procopiou PA, Browning C, Buckley JM, Clark KL, Fechner L, Gore PM, Hancock AP, Hodgson ST, Holmes DS, Kranz M et al.. (2011) The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis. J Med Chem, 54 (7): 2183-95. [PMID:21381763]

80. Ratnala VR, Swarts HG, VanOostrum J, Leurs R, DeGroot HJ, Bakker RA, DeGrip WJ. (2004) Large-scale overproduction, functional purification and ligand affinities of the His-tagged human histamine H1 receptor. Eur J Biochem, 271 (13): 2636-46. [PMID:15206929]

81. Sander LE, Lorentz A, Sellge G, Coëffier M, Neipp M, Veres T, Frieling T, Meier PN, Manns MP, Bischoff SC. (2006) Selective expression of histamine receptors H1R, H2R, and H4R, but not H3R, in the human intestinal tract. Gut, 55: 498-504. [PMID:16299042]

82. Schellenberg RR, Duff MJ, Foster A, Paddon HB. (1986) Histamine releases PGI2 from human pulmonary artery. Prostaglandins, 32 (2): 201-9. [PMID:3541061]

83. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl.), 124 (1-2): 57-73. [PMID:8935801]

84. Seifert R, Wenzel-Seifert K, Burckstummer T, Pertz HH, Schunack W, Dove S, Buschauer A, Elz S. (2003) Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther, 305 (3): 1104-15. [PMID:12626648]

85. Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, Abagyan R, Cherezov V, Liu W, Han GW et al.. (2011) Structure of the human histamine H1 receptor complex with doxepin. Nature, 475 (7354): 65-70. [PMID:21697825]

86. Sonobe Y, Nakane H, Watanabe T, Nakano K. (2004) Regulation of Con A-dependent cytokine production from CD4+ and CD8+ T lymphocytes by autosecretion of histamine. Inflamm Res, 53 (3): 87-92. [PMID:15021962]

87. Sánchez C, Hyttel J. (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol, 19 (4): 467-89. [PMID:10379421]

88. Thomson NC, Kerr JW. (1980) Effect of inhaled H1 and H2 receptor antagonist in normal and asthmatic subjects. Thorax, 35 (6): 428-34. [PMID:6449094]

89. Tilly BC, Tertoolen LG, Lambrechts AC, Remorie R, de Laat SW, Moolenaar WH. (1990) Histamine-H1-receptor-mediated phosphoinositide hydrolysis, Ca2+ signalling and membrane-potential oscillations in human HeLa carcinoma cells. Biochem J, 266 (1): 235-43. [PMID:2155607]

90. Todorov S, Zamfirova R. (1986) The role of H1- and H2-receptors in the modulatory effects of histaminergic agents on adrenergic neurotransmission in rat vas deferens. Methods Find Exp Clin Pharmacol, 8 (12): 705-9. [PMID:3027468]

91. von Coburg Y, Kottke T, Weizel L, Ligneau X, Stark H. (2009) Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett, 19 (2): 538-42. [PMID:19091563]

92. Whyment AD, Blanks AM, Lee K, Renaud LP, Spanswick D. (2006) Histamine excites neonatal rat sympathetic preganglionic neurons in vitro via activation of H1 receptors. J Neurophysiol, 95: 2492-2500. [PMID:16354729]

93. Wong BJ, Wilkins BW, Minson CT. (2004) H1 but not H2 histamine receptor activation contributes to the rise in skin blood flow during whole body heating in humans. J Physiol, 560: 941-948. [PMID:15375193]

94. Xie SX, Ghorai P, Ye QZ, Buschauer A, Seifert R. (2006) Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated Imidazolylpropylguanidines. J Pharmacol Exp Ther, 317 (1): 139-46. [PMID:16394198]

95. Yanai K, Son LZ, Endou M, Sakurai E, Nakagawasai O, Tadano T, Kisara K, Inoue I, Watanabe T, Watanabe T. (1998) Behavioural characterization and amounts of brain monoamines and their metabolites in mice lacking histamine H1 receptors. Neuroscience, 87 (2): 479-87. [PMID:9740406]

96. Yanai K, Son LZ, Endou M, Sakurai E, Watanabe T. (1998) Targeting disruption of histamine H1 receptors in mice: behavioral and neurochemical characterization. Life Sci, 62 (17-18): 1607-10. [PMID:9585144]

97. Zhou FW, Xu JJ, Zhao Y, LeDoux MS, Zhou FM. (2006) Opposite functions of histamine H1 and H2 receptors and H3 receptor in substantia nigra pars reticulata. J Neurophysiol, 96 (3): 1581-91. [PMID:16738217]

Contributors

Show »

How to cite this page